MiMedx Group Inc logo

MDXGMiMedx Group Inc

NASDAQ · Healthcare · Biotechnology

$4.58

+$0.07 (+1.44%)

MiMedx Group Inc (MDXG) is a biotechnology company listed on NASDAQ. It is led by Joseph H. Capper, based in 1775 West Oak Commons Court, NE, Marietta, GA, United States, 30062, with about 808 employees. MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors. Its patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. The company's wound care products include EPIFIX, EPICORD, EPIXPRESS, CHORIOFIX, EMERGE, CELERA, REGENKIT WOUND GEL, and EPIEFFECT sheets for use as protective barriers that enables a healthcare provider to select an appropriate size graft based on the size of the wound to reduce product waste. Its surgical and other product offerings consist of AMNIOFIX, AMNIOBURN, AMNIOCORD, AXIOFILL, HELIOGEN, and AMNIOEFFECT for applications in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery, and various orthopedic repairs and reconstructions. The company's products are used in the areas of wound care, burn, and surgical fields in healthcare. It sells its products through direct sales force and independent sales agents, as well as to individual customers and independent distributors in the United States. The company has a strategic alliance with Vaporox, Inc. for the promotion of their wound care offerings. The company was founded in 2006 and is headquartered in Marietta, Georgia.

Latest reported MDXG revenue for 2025-09-30 was $113.7M. Net income was $16.7M. Revenue was up 15.3% from 2025-06-30 to 2025-09-30. MDXG currently screens at market cap $537.7M and trailing P/E 18.1.

Use this MDXG page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the MDXG quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the MDXG SEC filings page. Lician reads the product cache first so this HTML stays unique to MiMedx Group Inc even when a live quote feed is slow.

About MiMedx Group Inc

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors. Its patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. The company's wound care products include EPIFIX, EPICORD, EPIXPRESS, CHORIOFIX, EMERGE, CELERA, REGENKIT WOUND GEL, and EPIEFFECT sheets for use as protective barriers that enables a healthcare provider to select an appropriate size graft based on the size of the wound to reduce product waste. Its surgical and other product offerings consist of AMNIOFIX, AMNIOBURN, AMNIOCORD, AXIOFILL, HELIOGEN, and AMNIOEFFECT for applications in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery, and various orthopedic repairs and reconstructions. The company's products are used in the areas of wound care, burn, and surgical fields in healthcare. It sells its products through direct sales force and independent sales agents, as well as to individual customers and independent distributors in the United States. The company has a strategic alliance with Vaporox, Inc. for the promotion of their wound care offerings. The company was founded in 2006 and is headquartered in Marietta, Georgia.

MDXG Key Statistics

Market Cap

$537.69M

Volume

711,020

Previous Close

$4.34

Day Range

$4.27$4.44

P/E Ratio

18.05

0

EPS

$0.28

Revenue

$348.88M

Net Income

$42.42M

Gross Profit

$0.00

Free Cash Flow

$0.00

Revenue Growth

+8.5%

Profit Margin

12.2%

Employees

808

MDXG Financials

Annual income statement in USD. Latest reported periods first.

MDXG annual income statement across FY2024, FY2023, FY2022, FY2021
LineFY2024FY2023FY2022FY2021
Revenue$348.88M$321.48M$267.84M$242.02M
Cost of Revenue$0.00$0.00$0.00$0.00
Gross Profit$0.00$0.00$0.00$0.00
Operating Income$0.00$0.00$0.00$0.00
Net Income$42.42M$58.23M-$30.20M-$10.29M
EPS (Diluted)$0.28$0.37-$0.33-$0.15

Total Assets

$263.92M

Total Debt

$0.00

Shareholders' Equity

$0.00

Cash & Equivalents

$104.42M

Operating Cash Flow

$66.20M

Free Cash Flow

$0.00

MiMedx Group Inc Company Information

CEO & Director
Joseph H. Capper
Headquarters
1775 West Oak Commons Court, NE, Marietta, GA, United States, 30062
Phone
770 651 9100
IPO / Founded
2007-08-22
Industry
Biotechnology
Data Updated:

Upcoming Events for MDXG